White House Secures $19.6B in Pharma Manufacturing Pledges

• The White House said nine additional pharmaceutical manufacturers have agreed to most-favored-nation pricing arrangements, bringing the total to 26 companies covering 89% of the branded drug market.
• The nine manufacturers committed at least $19.6 billion collectively to U.S. manufacturing, while UCB, Sun Pharma, Teva Pharmaceuticals and Astellas pledged APIs to the Strategic Active Pharmaceutical Ingredients Reserve.

The Trump administration is expanding its drug-pricing push to nine midsized pharmaceutical manufacturers, pairing most-favored-nation pricing commitments with at least $19.6 billion in planned U.S. manufacturing investment.

The White House announced Aug. 31 that Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB are part of the latest agreements. According to the administration, the additions bring the number of manufacturers with MFN deals to 26 and cover 89% of the branded drug market.

The pricing provisions give state Medicaid programs access to MFN prices for products from the nine manufacturers, according to the White House. The administration said the agreements cover medicines used for conditions including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions and several cancers. It also said the companies committed to MFN pricing for new innovative medicines they bring to market.

Exactly how those provisions translate into lower spending remains difficult to determine from the information released so far. Reuters reported that the government has not disclosed how many drugs the agreements cover or the discounts involved, leaving the savings for government programs and patients unclear. Medicaid already receives manufacturer discounts under existing law, and most Medicaid beneficiaries pay relatively little out of pocket for prescriptions. The underlying agreements have not been made public, leaving it unclear which drugs will receive lower prices and the size of additional Medicaid discounts.

For manufacturing and supply chain teams, the other half of the announcement may be more immediately relevant. The White House said the nine companies committed at least $19.6 billion collectively to U.S. manufacturing in the near term. Fierce Pharma reported that the manufacturing commitments accompany the pricing agreements, while some individual company announcements indicate tariff exemptions remain part of the broader MFN arrangements.

The agreements also put API inventories directly into the administration’s supply security strategy. According to the White House, UCB will contribute 163 tons of levetiracetam API to the Strategic Active Pharmaceutical Ingredients Reserve, while Sun Pharma will provide 71.4 tons of clindamycin and 6.75 tons of doxycycline. Teva will contribute 45 metric tons of metronidazole and 4.8 tons of amlodipine, and Astellas will provide 25 kg of tacrolimus.